# Moderna, Inc. (MRNA) FY2025 Q1 Balance Sheet

- Company: Moderna, Inc. (MRNA)
- Period: As of 2025-03-31
- Filing: Q1 FY2025 10-Q, filed 2025-05-01, accession number 0001682852-25-000034
- Page: https://plicit.ai/financials/mrna/fy2025-q1-balance-sheet
- Chart image: https://plicit.ai/charts/mrna-fy2025-q1-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2025-03-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 12,704,000,000 US dollars
- **Current assets**: 6,766,000,000 US dollars
- **Non-current assets**: 5,938,000,000 US dollars
- **Liabilities**: 2,638,000,000 US dollars
- **Current liabilities**: 1,604,000,000 US dollars
- **Non-current liabilities**: 1,034,000,000 US dollars
- **Equity**: 10,066,000,000 US dollars
- **Investments**: 4,352,000,000 US dollars
- **Cash and cash equivalents**: 1,623,000,000 US dollars
- **Prepaid expenses and other current assets**: 585,000,000 US dollars
- **Inventory**: 128,000,000 US dollars
- **Accounts receivable, net**: 78,000,000 US dollars
- **Investments, non-current**: 2,418,000,000 US dollars
- **Property, plant and equipment, net**: 2,212,000,000 US dollars
- **Right-of-use assets, operating leases**: 752,000,000 US dollars
- **Other non-current assets**: 556,000,000 US dollars
- **Accrued liabilities**: 1,001,000,000 US dollars
- **Other current liabilities**: 252,000,000 US dollars
- **Accounts payable**: 226,000,000 US dollars
- **Deferred revenue**: 125,000,000 US dollars
- **Operating lease liabilities, non-current**: 667,000,000 US dollars
- **Other non-current liabilities**: 274,000,000 US dollars
- **Deferred revenue, non-current**: 58,000,000 US dollars
- **Financing lease liabilities, non-current**: 35,000,000 US dollars
- **Retained earnings**: 9,074,000,000 US dollars
- **Additional paid-in capital**: 982,000,000 US dollars
- **Accumulated other comprehensive income (loss)**: 10,000,000 US dollars
- **Preferred stock, par value $0.0001; 162 shares authorized as of March 31, 2025 and December 31, 2024; no shares issued or outstanding at March 31, 2025 and December 31, 2024**: 0 US dollars
- **Common stock, par value $0.0001; 1,600 shares authorized as of March 31, 2025 and December 31, 2024; 387 and 386 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively**: 0 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.